| Aug 15 |
Scholar Rock’s apitegromab shows promise for non-ambulatory SMA
|
| Aug 9 |
Q2 2024 Scholar Rock Holding Corp Earnings Call
|
| Aug 8 |
Scholar Rock Holding Corporation (SRRK) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Scholar Rock GAAP EPS of -$0.60 beats by $0.02
|
| Aug 8 |
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
|
| Jul 23 |
Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
|
| Jul 8 |
Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts?
|
| Jun 24 |
Scholar Rock provides preclinical data for its investigational obesity candidate
|
| Jun 24 |
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
|
| Jun 3 |
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
|
